Results 131 to 140 of about 2,234,657 (224)

Drug resistant falciparum malaria and the use of artesunate-based combinations : focus on clinical trials sponsored by TDR [PDF]

Journal of Vector Borne Diseases, 2003
Antimalarial drug resistance has now become a serious global challenge and is the principal reasonfor the decline in antimalarial drug efficacy. Malaria endemic countries need inexpensive and efficaciousdrugs.
Walter R.J. Taylor, Jean Rigal & Piero L. Olliaro
doaj  

Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome. [PDF]

Cell Chem Biol, 2023
Deni I, Stokes BH, Ward KE, Fairhurst KJ, Pasaje CFA, Yeo T, Akbar S, Park H, Muir R, Bick DS, Zhan W, Zhang H, Liu YJ, Ng CL, Kirkman LA, Almaliti J, Gould AE, Duffey M, O'Donoghue AJ, Uhlemann AC, Niles JC, da Fonseca PCA, Gerwick WH, Lin G, Bogyo M, Fidock DA.   +25 more
europepmc   +1 more source

Resistance to Antimalarials [PDF]

Journal of Tropical Pediatrics, 2002
openaire   +2 more sources

Molecular Method Optimization to Identify Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) gene as a Predictor of Antimalarial Resistance

Biology, Medicine & Natural Product Chemistry
Several approaches have been designed to control malaria, a disease with high morbidity and mortality, but they face some hurdles. Antimalarial resistance is one of the major challenges for malaria elimination, so the detection of antimalarial resistance
Erma Sulistyaningsih, Rosita Dewi, Sheilla Rachmania, Irawan Fajar Kusuma, Muhammad Rizqi Kholifaturrohmy, Yunita Armiyanti, Sakinatus Sariroh Kholifaturrohmah, Made Prasanti Andriani   +7 more
doaj   +1 more source

Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. [PDF]

Malar J, 2023
Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, Awab GR, Baird JK, Brasil LW, Chu CS, Cui L, Daher A, do Socorro M Gomes M, Gonzalez-Ceron L, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Monteiro WM, Pereira DB, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Guerin PJ, Price RN, Simpson JA, Commons RJ, WWARN Vivax Adherence Study Group.   +38 more
europepmc   +1 more source

Targeted Amplicon Deep Sequencing for Monitoring Antimalarial Resistance Markers in Western Kenya. [PDF]

Antimicrob Agents Chemother, 2022
Osoti V, Akinyi M, Wamae K, Kimenyi KM, de Laurent Z, Ndwiga L, Gichuki P, Okoyo C, Kepha S, Mwandawiro C, Kandie R, Bejon P, Snow RW, Ochola-Oyier LI.   +13 more
europepmc   +1 more source

Historical evolution and molecular mechanisms of antimalarial drug resistance with emerging challenges and future directions

Discover Public Health
Malaria remains a major global public health concern, particularly in low- and middle-income countries, where it continues to cause substantial morbidity and mortality.
Osazuwa John Patrick, Adewale Allen Sokan-Adeaga, Rachael Olaide Emmanuel   +2 more
doaj   +1 more source

Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia. [PDF]

J Antimicrob Chemother, 2022
Mbye H, Mane K, Diop MF, Demba MA, Bojang F, Mohammed NI, Jeffries D, Quashie NB, D'Alessandro U, Amambua-Ngwa A.   +9 more
europepmc   +1 more source

Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors?

, 2002
We studied (in 1998 and 1999) some factors that may be linked to the spread of chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistance in 7 discrete communities in Uganda.
Watkins, W, Watkins, W., Langi, P., Egwang, T., Mutabingwa, TK, Langi, P, Mutabingwa, T.K., Bakyaita, N., Egwang, T, Bakyaita, N, D'Alessandro, U, d' Alessandro, U., Talisuna, A.O., Van Marck, E, Talisuna, AO, Van Marck, E.   +15 more
core   +1 more source

Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

Background: Therapeutic efcacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potentially preclude/pre-empt the detection of subsequent recrudescence of ...
Bassat Orellana, Quique, WorldWide Antimalarial Resistance Network Methodology Study Group   +1 more
core